WHI P180

a Janus kinase 3 inhibitor; structure in first source

Also Known As:

4-(3'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline; JANEX 3; JANEX-3; JANEX3; WHI-P180

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

1.	Hypersensitivity (Allergy) 01/01/1999 - "Further preclinical characterization of WHI-P180 may improve the efficacy of WHI-P180 in vivo and provide the basis for design of effective treatment and prevention programs for mast cell mediated allergic reactions."
2.	Phototoxic Dermatitis (Phototoxicity) 02/01/2009 - "WHI-P180 moderately inhibited ABCG2 function, exhibiting weak phototoxicity. "
3.	Anaphylaxis (Anaphylactic Shock) 01/01/1999 - "A cutaneous anaphylaxis model was used to examine the pharmacodynamic effects of WHI-P180 on anaphylaxis-associated vascular hyperpermeability. "